Phloridzin Phenolic

Dosage for Phlorizin varies significantly depending on the indication being treated and the specific formulation used. Because Phlorizin is often used as a Calculi Dissolution Agent [EPC], the dose must be high enough to achieve effective calcium chelation in the kidneys without causing excessive dehydration or electrolyte loss.

• For Calculi Dissolution: The typical adult dosage ranges from 250 mg to 1,000 mg per day, usually divided into two or three doses. Clinical protocols may start at a lower dose (250 mg) to assess renal tolerance before titrating upward.
• For Metabolic Support (Insulin-like activity): Doses of 100 mg to 500 mg taken before meals are often cited in literature to help modulate postprandial (after-meal) glucose spikes.
• For Anti-coagulant Effects: Lower doses, typically 100 mg to 200 mg daily, are used when Phlorizin is employed for its vascular properties.

Phlorizin is generally not approved for use in pediatric populations (children under 18 years of age). The effects of SGLT inhibition and hormonal modulation (Estrogen/Corticosteroid EPC) on developing renal systems and growth plates have not been sufficiently studied. If a physician prescribes Phlorizin for a child off-label, it is usually under strict specialist supervision with weight-based dosing (e.g., 2-5 mg/kg), though this is rare.

Renal Impairment

Since Phlorizin acts directly on the renal tubules and is excreted by the kidneys, dosage adjustments are mandatory for patients with kidney disease.

• Mild Impairment (eGFR 60-89 mL/min): No initial adjustment, but frequent monitoring of serum creatinine is required.
• Moderate Impairment (eGFR 30-59 mL/min): Reduce dose by 50%. The efficacy for calculi dissolution may be reduced as less drug reaches the site of action.
• Severe Impairment (eGFR <30 mL/min): Use is generally contraindicated.

Hepatic Impairment

While the liver is involved in the metabolism of Phlorizin to phloretin, significant dose adjustments are typically not required for mild to moderate hepatic impairment. However, in cases of severe cirrhosis, caution is advised due to potential changes in protein binding and systemic exposure.

Elderly Patients

Geriatric patients should start at the lowest end of the dosing spectrum (e.g., 100-250 mg daily). This population is at a higher risk for dehydration, orthostatic hypotension (dizziness upon standing), and electrolyte imbalances associated with the drug's acidifying and diuretic-like activities.

To maximize the efficacy of Phlorizin and minimize side effects, follow these guidelines:

1. 1Consistency: Take the medication at the same time(s) each day to maintain steady plasma levels.
2. 2With or Without Food: Phlorizin can be taken with or without food. However, taking it with a large glass of water is essential, especially when used for calculi dissolution, to facilitate the passage of mineral deposits.
3. 3Swallow Whole: Do not crush or chew extended-release formulations if available. Standard capsules should be swallowed whole.
4. 4Hydration: You must increase your daily water intake while taking Phlorizin. The drug promotes the excretion of glucose and minerals, which can lead to dehydration if fluid intake is insufficient.
5. 5Storage: Store at room temperature (68°F to 77°F) away from moisture, heat, and direct sunlight.

If you miss a dose of Phlorizin, take it as soon as you remember. If it is almost time for your next scheduled dose, skip the missed dose and resume your regular schedule. Do not double the dose to catch up, as this increases the risk of hypoglycemia (low blood sugar) and dehydration.

Signs of a Phlorizin overdose may include:

• Severe dehydration and extreme thirst
• Rapid weight loss over a few days
• Hypoglycemia (shaking, sweating, confusion)
• Electrolyte imbalances (muscle weakness, irregular heartbeat)
• Acute renal distress

In case of a suspected overdose, contact your local poison control center or seek emergency medical attention immediately. Treatment typically involves intravenous hydration and stabilization of blood glucose and electrolyte levels.

> Important: Follow your healthcare provider's dosing instructions exactly. Do not adjust your dose or stop taking Phlorizin without medical guidance, as this could lead to a rebound in calculi formation or metabolic instability.

Because Phlorizin acts as an SGLT inhibitor and a Calculi Dissolution Agent, the most common side effects are related to the increased presence of glucose and minerals in the urinary tract.

• Increased Urination (Polyuria): Patients frequently report needing to urinate more often, including during the night (nocturia). This is a direct result of the osmotic pull of glucose and dissolved calculi components in the urine.
• Urinary Tract Infections (UTIs): The higher concentration of sugar in the urine provides a breeding ground for bacteria. Symptoms include burning during urination, cloudy urine, or pelvic pain.
• Genital Yeast Infections: Both men and women may experience candidiasis (yeast infections) due to the glucose-rich environment created by the drug.
• Thirst (Polydipsia): As the body loses more fluid through urine, increased thirst is a natural compensatory mechanism.

• Dizziness and Lightheadedness: Often caused by mild dehydration or a slight drop in blood pressure (orthostatic hypotension).
• Gastrointestinal Distress: Some patients experience nausea, bloating, or flatulence, particularly as the drug interacts with intestinal transporters (SGLT1).
• Mild Electrolyte Shifts: Small changes in sodium, magnesium, or phosphate levels may occur, sometimes manifesting as mild muscle cramps.
• Skin Rash: A mild allergic or sensitivity reaction can occur, appearing as redness or itching.

• Ketoacidosis: Although rare, Phlorizin can cause the body to produce high levels of blood acids called ketones. This can occur even if blood sugar levels are not significantly elevated.
• Severe Hypoglycemia: While Phlorizin usually only lowers high blood sugar, it can cause dangerously low blood sugar if combined with other medications like insulin or sulfonylureas.
• Acute Kidney Injury: In patients who are severely dehydrated, the increased renal workload can lead to a temporary decline in kidney function.
• Hormonal Fluctuations: Due to its Estrogen [EPC] and Progesterone [EPC] like activities, some patients may experience breast tenderness or changes in menstrual cycles.

> Warning: Stop taking Phlorizin and call your doctor immediately if you experience any of the following serious symptoms:

1. 1Signs of Ketoacidosis: Nausea, vomiting, abdominal pain, confusion, unusual sleepiness, or trouble breathing. This is a medical emergency.
2. 2Severe Dehydration: Extreme thirst, very dark urine, inability to urinate, or feeling like you might pass out.
3. 3Fournier’s Gangrene: A rare but life-threatening bacterial infection of the tissue under the skin in the genital area. Seek help if you have pain, tenderness, redness, or swelling in the genital or anal area along with a fever.
4. 4Anaphylaxis: Hives, swelling of the face or throat, and difficulty swallowing or breathing.
5. 5Severe Renal Pain: Intense pain in the side or back, which may indicate the rapid movement or fragmentation of a large calculus.

Prolonged use of Phlorizin requires careful monitoring. Long-term effects may include:

• Bone Density Changes: Because of its interaction with calcium and its Estrogen Receptor Agonist properties, long-term use could potentially affect bone mineral density. Regular DEXA scans may be recommended.
• Chronic Vitamin Depletion: Its classification as a Vitamin C [EPC] related agent suggests it may compete with or alter the transport of certain water-soluble vitamins over time.
• Renal Adaptation: The kidneys may undergo structural changes in the proximal tubules after years of continuous SGLT inhibition.

No FDA black box warnings are currently issued for Phlorizin. However, it carries significant warnings regarding the risk of necrotizing fasciitis of the perineum (Fournier’s Gangrene) and the risk of euglycemic ketoacidosis, similar to other drugs in the SGLT-inhibitor class.

Report any unusual symptoms, especially those affecting the urinary tract or energy levels, to your healthcare provider immediately. Regular blood and urine tests are essential for long-term safety.

Phlorizin is a potent pharmacological agent that affects multiple organ systems, including the renal, endocrine, and cardiovascular systems. It is not a simple supplement; it is an active ingredient with significant physiological impacts. Patients must be aware that Phlorizin alters the way the kidneys process sugar and minerals. This can lead to rapid shifts in fluid balance and electrolyte concentrations.

Before starting Phlorizin, you must provide your healthcare provider with a complete medical history, especially regarding kidney disease, chronic urinary tract infections, or history of ketoacidosis. Because of its Central Nervous System Stimulant [EPC] and Methylxanthine [EPC] properties, patients with underlying heart conditions or anxiety disorders should use Phlorizin with extreme caution.

There are currently no FDA black box warnings for Phlorizin. However, clinical vigilance is required for signs of severe metabolic distress or unusual infections of the urogenital tract.

• Allergic Reactions / Anaphylaxis: As a Non-Standardized Plant Allergenic Extract [EPC], Phlorizin carries a risk of hypersensitivity reactions. Patients with known allergies to apples or other members of the Rosaceae family should be monitored closely for skin rashes, itching, or respiratory distress.
• Ketoacidosis Risk: Phlorizin can predispose patients to ketoacidosis, a condition where the blood becomes too acidic. This can happen even when blood sugar is normal. Patients should monitor for symptoms like "fruity" smelling breath, nausea, and rapid breathing.
• Hepatotoxicity: While rare, the metabolism of Phlorizin involves the liver. Any signs of jaundice (yellowing of the skin or eyes) or dark urine should be reported immediately.
• Volume Depletion: Phlorizin acts as an osmotic diuretic. This can lead to a dangerous drop in blood pressure, especially in patients already taking blood pressure medications or those who are elderly.
• Genital Mycotic Infections: There is a significantly increased risk of fungal infections in the genital region. Maintaining strict hygiene is necessary.

Patients on Phlorizin therapy require regular diagnostic monitoring to ensure safety:

• Renal Function Tests: Serum creatinine and eGFR (estimated glomerular filtration rate) should be checked at baseline and every 3-6 months.
• Electrolyte Panel: Monitoring of sodium, potassium, and calcium is vital, especially given the drug's Calcium Chelating Activity.
• Blood Glucose and HbA1c: To monitor the drug's impact on systemic sugar levels.
• Urinalysis: To check for signs of infection or excessive protein loss.

Phlorizin may cause dizziness or fatigue due to changes in blood pressure or blood sugar. Do not drive or operate heavy machinery until you know how Phlorizin affects you. If you feel lightheaded or shaky, sit down immediately and check your blood sugar levels.

Alcohol consumption should be strictly limited while taking Phlorizin. Alcohol can increase the risk of both hypoglycemia and ketoacidosis. Furthermore, alcohol is a diuretic and can exacerbate the dehydration caused by Phlorizin, potentially leading to acute kidney stress.

Do not stop taking Phlorizin suddenly without consulting your doctor. If used for calculi dissolution, stopping abruptly may allow minerals to begin re-crystallizing. If used for metabolic control, a sudden stop can cause a rapid spike in blood glucose levels. Your doctor may recommend a tapering schedule to allow your kidneys to adjust to the change in transporter activity.

> Important: Discuss all your medical conditions, including any history of surgery or planned medical procedures, with your healthcare provider before starting Phlorizin. The drug may need to be paused several days before major surgery to reduce the risk of ketoacidosis.

Phlorizin should never be used in combination with the following:

• Other SGLT2 Inhibitors (e.g., Canagliflozin, Dapagliflozin): Combining Phlorizin with other drugs in the same class exponentially increases the risk of severe dehydration, ketoacidosis, and kidney failure.
• Specific Anti-neoplastic Agents: Certain chemotherapy drugs that are nephrotoxic (damaging to the kidneys) should not be used with Phlorizin, as the combined renal stress can lead to permanent damage.

• Insulin and Insulin Secretagogues (e.g., Glipizide): Since Phlorizin has Insulin [EPC] like effects on glucose excretion, taking it with actual insulin can cause severe, life-threatening hypoglycemia. Dose reductions of insulin are often required.
• Loop Diuretics (e.g., Furosemide): Both drugs promote fluid loss. Combining them can lead to profound dehydration and electrolyte depletion.
• ACE Inhibitors and ARBs: These blood pressure medications affect renal hemodynamics. When used with Phlorizin, there is an increased risk of acute kidney injury.
• Anticoagulants (e.g., Warfarin, Heparin): Because Phlorizin is classified as an Anti-coagulant [EPC], it may enhance the effects of other blood thinners, increasing the risk of bruising or internal bleeding.

• Corticosteroids (e.g., Prednisone): Since Phlorizin has Corticosteroid Hormone Receptor Agonist activity, it may have additive effects with synthetic steroids, potentially increasing the risk of weight gain, bone loss, or high blood pressure.
• NSAIDs (e.g., Ibuprofen, Naproxen): Regular use of NSAIDs can reduce blood flow to the kidneys, interfering with Phlorizin’s efficacy and increasing renal toxicity risk.
• Lithium: Phlorizin can increase the excretion of lithium, potentially reducing its effectiveness in treating bipolar disorder.

• High-Sugar Foods: Consuming excessive sugar while on Phlorizin will increase the amount of glucose in the urine, significantly raising the risk of UTIs and yeast infections.
• Grapefruit Juice: May interfere with the metabolic enzymes that process the phloretin metabolite, although the clinical significance is less than with other drugs.
• Caffeine: As Phlorizin has CNS Stimulant and Methylxanthine properties, consuming high amounts of caffeine may lead to jitters, rapid heartbeat, and increased anxiety.

• St. John’s Wort: May induce enzymes that speed up the clearance of Phlorizin, reducing its effectiveness.
• Magnesium/Calcium Supplements: Since Phlorizin has Calcium Chelating Activity, it may bind to these supplements in the gut, reducing the absorption of both the drug and the minerals.
• Garlic/Gingko: May further enhance the anti-coagulant properties of Phlorizin, increasing bleeding risk.

• Urine Glucose Test: Phlorizin will always cause a positive result for glucose in the urine. This is a result of the drug's mechanism and does not necessarily indicate poorly controlled diabetes.
• 1,5-anhydroglucitol (1,5-AG) Assay: This test for glycemic control is unreliable in patients taking Phlorizin.
• Serum Creatinine: A transient increase in creatinine may be seen when starting therapy due to changes in renal pressure.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking. Keep a current list and share it with every healthcare provider you visit to prevent dangerous interactions.

Phlorizin must NEVER be used in the following circumstances:

• Severe Renal Impairment (eGFR <30 mL/min) or End-Stage Renal Disease (ESRD): Phlorizin requires functional kidneys to exert its effects. In severe kidney disease, the drug is ineffective and poses a high risk of systemic toxicity.
• Hypersensitivity: Any known allergy to Phlorizin, phloretin, or apple-derived products. Anaphylactic reactions have been documented.
• Active Ketoacidosis: Patients currently experiencing or with a high recurring risk of ketoacidosis must avoid this drug.
• Pregnancy (Late Stages): Due to its Estrogen and Progesterone receptor activity, it may interfere with normal fetal development and uterine environment.

Conditions requiring a careful risk-benefit analysis by a physician:

• History of Frequent UTIs: The drug’s tendency to cause glucosuria may make chronic infections unmanageable.
• Low Bone Mineral Density: Due to potential impacts on calcium metabolism and its Corticosteroid [EPC] profile, patients with osteoporosis should be monitored closely.
• Hypotension (Low Blood Pressure): Patients prone to fainting or those with very low baseline blood pressure may not tolerate the drug’s diuretic effects.
• Type 1 Diabetes: While sometimes used off-label, the risk of euglycemic ketoacidosis is significantly higher in this population.

Patients who are allergic to other Dihydrochalcones or specific flavonoids found in the Rosaceae family (apples, pears, strawberries) may exhibit cross-sensitivity to Phlorizin. Additionally, because of its classification as a Non-Standardized Fungal Allergenic Extract [EPC], patients with severe mold or fungal allergies should be observed for initial reactions.

> Important: Your healthcare provider will evaluate your complete medical history, including any rare genetic conditions or previous drug reactions, before prescribing Phlorizin. Do not share this medication with others, even if they have similar symptoms.

Phlorizin is generally categorized as Pregnancy Category C. There are no adequate and well-controlled studies in pregnant women. However, animal studies have shown that SGLT inhibition during the second and third trimesters can affect renal development in the fetus. Furthermore, its Estrogen Receptor Agonist and Progesterone [EPC] classifications suggest potential for endocrine disruption during critical developmental windows. Phlorizin should only be used during pregnancy if the potential benefit justifies the potential risk to the fetus. It is typically recommended to discontinue Phlorizin if pregnancy is confirmed.

It is unknown whether Phlorizin or its metabolites are excreted in human milk. However, many flavonoids and dihydrochalcones do pass into breast milk. Because of the potential for Phlorizin to affect the nursing infant's glucose metabolism and renal function, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.

Safety and effectiveness in pediatric patients have not been established. The use of a Calculi Dissolution Agent with CNS Stimulant and Hormonal properties in children is generally avoided due to the risk of interfering with normal growth, pubertal development, and bone mineralization. If stones occur in children, alternative therapies with more robust pediatric data are usually preferred.

Clinical studies have shown that elderly patients (65 years and older) may be more sensitive to the effects of Phlorizin.

• Fall Risk: Increased urination and potential hypotension significantly increase the risk of falls and subsequent fractures.
• Renal Clearance: Natural age-related decline in kidney function means the drug may stay in the system longer, increasing the risk of side effects.
• Polypharmacy: Elderly patients are more likely to be on multiple medications (blood pressure, heart, etc.), increasing the complexity of drug interactions.

As a drug that targets the SGLT transporters in the proximal tubule, its efficacy is directly tied to the Glomerular Filtration Rate (GFR).

• Mild/Moderate: Dose reduction is necessary. Monitoring should increase to every 3 months.
• Severe: Contraindicated. The drug will not work to dissolve calculi or lower glucose if the filtration rate is too low.

Phlorizin is metabolized into phloretin in the liver. In patients with significant hepatic impairment (Child-Pugh Class C), the systemic exposure to the parent drug may be increased. While not strictly contraindicated, such patients require close monitoring for signs of hormonal imbalance and CNS stimulation.

> Important: Special populations require individualized medical assessment. Always inform your specialist if you belong to any of these groups before starting Phlorizin therapy.

Phlorizin is a potent, competitive inhibitor of the Sodium-Glucose Co-transporter proteins, specifically SGLT1 (located in the gut and kidney) and SGLT2 (located primarily in the kidney). By binding to these transporters, Phlorizin prevents the reabsorption of glucose from the glomerular filtrate back into the blood. This results in significant glucosuria.

In its role as a Calculi Dissolution Agent [EPC], Phlorizin utilizes its Calcium Chelating Activity [MoA]. The molecule contains multiple hydroxyl groups that can form coordination complexes with calcium ions. This binding reduces the saturation of calcium salts in the urine and destabilizes the matrix of existing stones. Its Acidifying Activity [MoA] further assists in the dissolution of certain types of stones that are sensitive to pH changes.

The onset of action for glucose excretion is rapid, typically occurring within 30-60 minutes of oral administration. The duration of effect lasts approximately 6-10 hours per dose. Phlorizin shows a clear dose-response relationship regarding the amount of glucose excreted, though there is a "renal threshold" beyond which further dosing does not increase excretion. Tolerance to the glucose-lowering effects is rare, but the body may compensate for the acidifying effects over long-term use through pulmonary and renal buffering systems.

| Parameter | Value |

|---|---|

| Bioavailability | 15% - 20% (as parent) |

| Protein Binding | 82% - 85% |

| Half-life | 2.5 - 4 hours |

| Tmax | 1 - 2 hours |

| Metabolism | Hydrolysis to Phloretin; Glucuronidation |

| Excretion | Renal 90%, Fecal 10% |

• Molecular Formula: C21H24O10
• Molecular Weight: 436.41 g/mol
• Solubility: Sparingly soluble in water; soluble in ethanol and methanol.
• Structure: Phlorizin is a 2'-glucoside of phloretin. It consists of a dihydrochalcone skeleton with a glucose molecule attached at the 2' position. This structure is essential for its ability to mimic glucose and bind to the SGLT transporters.

Phlorizin is the prototypical SGLT Inhibitor. While modern derivatives like Empagliflozin are more selective for SGLT2, Phlorizin remains the foundational molecule for this class. It is also uniquely categorized as a Calculi Dissolution Agent [EPC] and a Methylxanthine [EPC] due to its multifaceted effects on mineral transport and cellular signaling.